CPH News: Halucenex Life Sciences Inc. targets Australian market following landmark TGA decision - 9th Feb 2023, 4:36am

[annb0t]

The wholly-owned Creso Pharma subsidiary is currently conducting clinical trials of its synthetic psilocybin formulation as treatment for mental health conditions

NEDLANDS, Australia, Feb. 8, 2023 /PRNewswire/ -- Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma') is pleased to announce its wholly-owned psychedelics subsidiary, Halucenex Life Sciences Inc. ('Halucenex'), is exploring opportunities to register its synthetic psilocybin formulation for the Australian market following recent r...

>>> Read more: Halucenex Life Sciences Inc. targets Australian market following landmark TGA decision